{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:10:07Z","timestamp":1749895807989,"version":"3.41.0"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01499-8","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T05:12:43Z","timestamp":1747890763000},"page":"839-840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to Comment on \u201cExamining Consistency Across NICE Single Technology Appraisals: A Review of Appraisals for Paroxysmal Nocturnal Haemoglobinuria\u201d"],"prefix":"10.1007","volume":"43","author":[{"given":"Daniel","family":"Gallacher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"1499_CR1","doi-asserted-by":"publisher","unstructured":"Farrar B, Gladwell D, Woods M. Comment on \"Examining consistency across NICE single technology appraisals: a review of appraisals for paroxysmal nocturnal haemoglobinuria\". Pharmacoeconomics. 2025 https:\/\/doi.org\/10.1007\/s40273-025-01500-4.","DOI":"10.1007\/s40273-025-01500-4"},{"issue":"5","key":"1499_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40273-025-01472-5","volume":"43","author":"J Donoghue","year":"2025","unstructured":"Donoghue J, Youngs M, Reeve A, Vydyula K, Kunst N, Trikha R, et al. Examining consistency across NICE single technology appraisals: a review of appraisals for paroxysmal nocturnal haemoglobinuria. Pharmacoeconomics. 2025;43(5):499\u2013508.","journal-title":"Pharmacoeconomics"},{"key":"1499_CR3","unstructured":"NICE. MTA timeline. Available from: https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/process\/mta-timeline. Accessed 1 Apr 2025."},{"key":"1499_CR4","unstructured":"NICE. TA814 documents. Available from: https:\/\/www.nice.org.uk\/guidance\/ta814\/documents\/1. Accessed 1 Apr 2025."},{"issue":"3","key":"1499_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10728-019-00381-x","volume":"28","author":"V Charlton","year":"2020","unstructured":"Charlton V. NICE and fair? Health technology assessment policy under the UK\u2019s National Institute for Health and Care Excellence, 1999\u20132018. Health Care Anal. 2020;28(3):193\u2013227.","journal-title":"Health Care Anal"},{"key":"1499_CR6","unstructured":"Wellcome. Evidence Synthesis Infrastructure Collaborative. Available from: https:\/\/wellcome.org\/news\/evidence-synthesis-infrastructure-collaborative. Accessed 1 Apr 2025."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01499-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01499-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01499-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T09:48:31Z","timestamp":1749894511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01499-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":6,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1499"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01499-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"type":"print","value":"1170-7690"},{"type":"electronic","value":"1179-2027"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"6 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this letter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel Gallacher was a member of the EAG for the appraisal of danicopan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}}]}}